CONTEXT: Besides (123)I-metaiodobenzylguanidine (MIBG), positron emission tomography (PET) agents are available for the localization of paraganglioma (PGL), including (18)F-3,4-dihydroxyphenylalanine (DOPA), (18)F-fluoro-2-deoxy-D-glucose ((18)F-FDG), and (18)F-fluorodopamine ((18)F-FDA). OBJECTIVE: The objective of the study was to establish the optimal approach to the functional imaging of PGL and examine the link between genotype-specific tumor biology and imaging. DESIGN: This was a prospective observational study. INTERVENTION: There were no interventions. PATIENTS: Fifty-two patients (28 males, 24 females, aged 46.8 +/- 14.2 yr): 20 with nonmetastatic PGL (11 adrenal), 28 with metastatic PGL (13 adrenal), and four in whom PGL was ruled out; 22 PGLs were of the succinate dehydrogenase subunit B (SDHB) genotype. MAIN OUTCOME MEASURES: Sensitivity of (18)F-DOPA, (18)F-FDG, and (18)F-FDA PET, (123)I-MIBG scintigraphy, computed tomography (CT), and magnetic resonance imaging (MRI) for the localization of PGL were measured. RESULTS: Sensitivities for localizing nonmetastatic PGL were 100% for CT and/or MRI, 81% for (18)F-DOPA PET, 88% for (18)F-FDG PET/CT, 78% for (18)F-FDA PET/CT, and 78% for (123)I-MIBG scintigraphy. For metastatic PGL, sensitivity in reference to CT/MRI was 45% for (18)F-DOPA PET, 74% for (18)F-FDG PET/CT, 76% for (18)F-FDA PET/CT, and 57% for (123)I-MIBG scintigraphy. In patients with SDHB metastatic PGL, (18)F-FDA and (18)F-FDG have a higher sensitivity (82 and 83%) than (123)I-MIBG (57%) and (18)F-DOPA (20%). CONCLUSIONS: (18)F-FDA PET/CT is the preferred technique for the localization of the primary PGL and to rule out metastases. Second best, equal alternatives are (18)F-DOPA PET and (123)I-MIBG scintigraphy. For patients with known metastatic PGL, we recommend (18)F-FDA PET in patients with an unknown genotype, (18)F-FDG or (18)F-FDA PET in SDHB mutation carriers, and (18)F-DOPA or (18)F-FDA PET in non-SDHB patients.
CONTEXT: Besides (123)I-metaiodobenzylguanidine (MIBG), positron emission tomography (PET) agents are available for the localization of paraganglioma (PGL), including (18)F-3,4-dihydroxyphenylalanine (DOPA), (18)F-fluoro-2-deoxy-D-glucose ((18)F-FDG), and (18)F-fluorodopamine ((18)F-FDA). OBJECTIVE: The objective of the study was to establish the optimal approach to the functional imaging of PGL and examine the link between genotype-specific tumor biology and imaging. DESIGN: This was a prospective observational study. INTERVENTION: There were no interventions. PATIENTS: Fifty-two patients (28 males, 24 females, aged 46.8 +/- 14.2 yr): 20 with nonmetastatic PGL (11 adrenal), 28 with metastatic PGL (13 adrenal), and four in whom PGL was ruled out; 22 PGLs were of the succinate dehydrogenase subunit B (SDHB) genotype. MAIN OUTCOME MEASURES: Sensitivity of (18)F-DOPA, (18)F-FDG, and (18)F-FDA PET, (123)I-MIBG scintigraphy, computed tomography (CT), and magnetic resonance imaging (MRI) for the localization of PGL were measured. RESULTS: Sensitivities for localizing nonmetastatic PGL were 100% for CT and/or MRI, 81% for (18)F-DOPA PET, 88% for (18)F-FDG PET/CT, 78% for (18)F-FDA PET/CT, and 78% for (123)I-MIBG scintigraphy. For metastatic PGL, sensitivity in reference to CT/MRI was 45% for (18)F-DOPA PET, 74% for (18)F-FDG PET/CT, 76% for (18)F-FDA PET/CT, and 57% for (123)I-MIBG scintigraphy. In patients with SDHB metastatic PGL, (18)F-FDA and (18)F-FDG have a higher sensitivity (82 and 83%) than (123)I-MIBG (57%) and (18)F-DOPA (20%). CONCLUSIONS: (18)F-FDA PET/CT is the preferred technique for the localization of the primary PGL and to rule out metastases. Second best, equal alternatives are (18)F-DOPA PET and (123)I-MIBG scintigraphy. For patients with known metastatic PGL, we recommend (18)F-FDA PET in patients with an unknown genotype, (18)F-FDG or (18)F-FDA PET in SDHB mutation carriers, and (18)F-DOPA or (18)F-FDA PET in non-SDHBpatients.
Authors: Henri J L M Timmers; Anna Kozupa; Graeme Eisenhofer; Margarita Raygada; Karen T Adams; Daniel Solis; Jacques W M Lenders; Karel Pacak Journal: J Clin Endocrinol Metab Date: 2007-01-02 Impact factor: 5.958
Authors: Priya Kaji; Jorge A Carrasquillo; W Marston Linehan; Clara C Chen; Graeme Eisenhofer; Peter A Pinto; Edwin W Lai; Karel Pacak Journal: Eur J Endocrinol Date: 2007-04 Impact factor: 6.664
Authors: Henri J L M Timmers; Mohiuddin Hadi; Jorge A Carrasquillo; Clara C Chen; Lucia Martiniova; Millie Whatley; Alexander Ling; Graeme Eisenhofer; Karen T Adams; Karel Pacak Journal: J Nucl Med Date: 2007-09-14 Impact factor: 10.057
Authors: Farzin Imani; Vatche G Agopian; Martin S Auerbach; Martin A Walter; Firoozeh Imani; Matthias R Benz; Rebecca A Dumont; Chi Kien Lai; Johannes G Czernin; Michael W Yeh Journal: J Nucl Med Date: 2009-03-16 Impact factor: 10.057
Authors: Ioannis Ilias; Clara C Chen; Jorge A Carrasquillo; Millie Whatley; Alexander Ling; Ivica Lazúrová; Karen T Adams; Shiromi Perera; Karel Pacak Journal: J Nucl Med Date: 2008-09-15 Impact factor: 10.057
Authors: D Taïeb; L Tessonnier; F Sebag; P Niccoli-Sire; I Morange; C Colavolpe; C De Micco; A Barlier; F F Palazzo; J F Henry; O Mundler Journal: Clin Endocrinol (Oxf) Date: 2008-04-03 Impact factor: 3.478
Authors: Kunwar S S Bhatia; Mohamed M Ismail; Anju Sahdev; Andrea G Rockall; Kieran Hogarth; Ana Canizales; Norbert Avril; John P Monson; Ashley B Grossman; Rodney H Reznek Journal: Clin Endocrinol (Oxf) Date: 2008-04-03 Impact factor: 3.478
Authors: Jay S Fonte; Jeremyjones F Robles; Clara C Chen; James Reynolds; Millie Whatley; Alexander Ling; Leilani B Mercado-Asis; Karen T Adams; Victoria Martucci; Tito Fojo; Karel Pacak Journal: Endocr Relat Cancer Date: 2012-02-13 Impact factor: 5.678
Authors: Désirée Deandreis; Sophie Leboulleux; Caroline Caramella; Martin Schlumberger; Eric Baudin Journal: Horm Cancer Date: 2011-12 Impact factor: 3.869
Authors: Lucia Martiniova; Susannah Cleary; Edwin W Lai; Dale O Kiesewetter; Jurgen Seidel; Linda F Dawson; Jacqueline K Phillips; David Thomasson; Xiaoyuan Chen; Graeme Eisenhofer; James F Powers; Richard Kvetnansky; Karel Pacak Journal: Nucl Med Biol Date: 2011-09-29 Impact factor: 2.408
Authors: Emilio Bombardieri; Francesco Giammarile; Cumali Aktolun; Richard P Baum; Angelika Bischof Delaloye; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Giovanna Pepe; Sven N Reske; Maria R Castellani; Arturo Chiti Journal: Eur J Nucl Med Mol Imaging Date: 2010-12 Impact factor: 9.236